Agios Pharmaceuticals, Inc. (AGIO): Price and Financial Metrics
Today's Latest Price: $55.69 USD
Jul 2 4:00pm Add AGIO to Watchlist Sign Up POWR Components:
Buy & Hold Grade
Peer Grade Industry Rank AGIO Stock Summary Of note is the ratio of Agios Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 13.04% of US stocks have a lower such ratio. With a price/sales ratio of 21.08, Agios Pharmaceuticals Inc has a higher such ratio than 93.11% of stocks in our set. Revenue growth over the past 12 months for Agios Pharmaceuticals Inc comes in at 50.87%, a number that bests 89.82% of the US stocks we're tracking. Stocks with similar financial metrics, market capitalization, and price volatility to Agios Pharmaceuticals Inc are BPMC, RARE, DRNA, PRNB, and RGNX. AGIO's SEC filings can be seen here. And to visit Agios Pharmaceuticals Inc's official web site, go to www.agios.com. AGIO Price/Volume Stats
3.84B Agios Pharmaceuticals, Inc. (AGIO) Company Bio
Agios Pharmaceuticals is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. The company was founded in 2007 and is based in Cambridge, Massachusetts.
AGIO Latest News Stream
All News Types Commentary Corp. News Cramer Debt Offering Downgrade Earnings Mgmt Change New Coverage (Bullish) New Coverage (Neutral) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Stock Offering Upgrade
Event/Time News Detail Loading, please wait... Latest AGIO News From Around the Web
Below are the latest news stories about Agios Pharmaceuticals Inc that investors may wish to consider to help them evaluate AGIO as an investment opportunity.
Today we will run through one way of estimating the intrinsic value of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by...
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CAMBRIDGE, Mass., June 17, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.
Q1 2020 Agios Pharmaceuticals Inc Earnings Call
Read More 'AGIO' Stories Here
AGIO Price Returns
-42.06% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.871 seconds.